{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:15:03Z","timestamp":1790666103592,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.esmoop.2022.100571","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T05:57:33Z","timestamp":1661666253000},"page":"100571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1\/2 metastatic breast cancer: results from a phase II basket study"],"prefix":"10.1016","volume":"7","author":[{"given":"V.","family":"Boni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Huidobro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100571_bib1","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2147\/CMAR.S189627","article-title":"A\u00a0systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer","volume":"11","author":"Forbes","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2022.100571_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100571_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","article-title":"BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis","volume":"5","author":"Foulkes","year":"2006","journal-title":"Fam Cancer"},{"key":"10.1016\/j.esmoop.2022.100571_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11864-018-0540-2","article-title":"Update on PARP inhibitors in breast cancer","volume":"19","author":"Zimmer","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.esmoop.2022.100571_bib5","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100571_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100571_bib7","doi-asserted-by":"crossref","first-page":"25885","DOI":"10.18632\/oncotarget.8292","article-title":"Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair","volume":"7","author":"Lima","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100571_bib8","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in\u00a0vitro and in\u00a0vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100571_bib9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamaria Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2022.100571_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature13374","article-title":"BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2","volume":"511","author":"Bhatia","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100571_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.molcel.2003.08.010","article-title":"Cotranscriptionally formed DNA:RNA hybrids mediate transcription elongation impairment and transcription-associated recombination","volume":"12","author":"Huertas","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.esmoop.2022.100571_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100571_bib13","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100571_bib14","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1200\/JCO.2018.78.6558","article-title":"Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy","volume":"36","author":"Cruz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100571_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100571_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2017.04.006","article-title":"Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: a subset analysis of a dedicated phase II trial","volume":"34","author":"Ghouadni","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2022.100571_bib17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdx111","article-title":"Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant\/refractory advanced ovarian cancer","volume":"28","author":"Poveda","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100571_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2022.100571_bib19","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","article-title":"Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study","volume":"28","author":"Subbiah","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:13Z","timestamp":1761856093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2059702922002010"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100571","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1\/2 metastatic breast cancer: results from a phase II basket study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100571"}}